We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Peripheral Blood Smears Still Need Evaluation

By LabMedica International staff writers
Posted on 22 Jun 2017
When the first automated hematology analyzers appeared in clinical laboratories in the 1960s, they ushered in a welcomed workflow change for bench technologists. More...
These automated analyzers replaced hemocytometers, though the need for differential counting remained.

This evolution in hematology workflows has continued to this day, with automated instruments performing ever more cellular analysis, resulting in more focused roles for technologists and pathologists. However, certain characteristics of peripheral blood morphology still do not lend themselves easily to evaluation by automated analyzers.

A clinical associate professor at the University of Florida (Gainesville, FL, USA) has written that one limitation that has remained constant from the earliest hematology analyzers to today’s cutting-edge flow cytometers is that a single cell still must pass through an aperture for analysis. In order to maintain laminar flow, the cell must also be sphered, which is most often accomplished with a proprietary sphering reagent. The exact classification of abnormally shaped red cells, for example, sickle cells, target cells, and schistocytes, still requires morphologic review of stained slides.

In addition red cell and white cell inclusions, particularly infectious organisms such as malaria or histoplasmosis, can be seen in stained blood smears but are not routinely detected by most automated hematology analyzers. Because of the extensive morphologic variability of many circulating hematologic malignancies, automated systems cannot precisely characterize these cells. Most analyzers, however, aid in characterizing these cells by pre-classifying them as abnormal (through large unstained cell classification or flagging) and prompting manual review of slides.

Analyzers that have digital morphology capabilities, such as the CellaVision or the Bloodhound systems, are inaugurating a new era of cellular analysis. As these instruments’ algorithms continue to be refined, this technology might evolve from a pre-classifier method to a more enhanced and robust method for precise characterization. The accuracy of an automated differential count depends on the analytical system used. However, given that most automated counters literally characterize thousands of white cells for each analysis, the classic 100-cell manual differential count in comparison falls short when it comes to precision. Sherri D. Flax, MD, published her article on June 1, 2017, in the journal Clinical Laboratory News.

Related Links:
University of Florida


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.